Vyome Holdings (HIND) EPS (Basic) Growth (3y) (2020 - 2026)
Vyome Holdings (HIND) EPS (Basic) Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | -38.31% |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | 92.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.11% |
| Mar 31, 2026 | 97.24% |
| Dec 31, 2025 | 98.58% |
| Sep 30, 2025 | 97.29% |
| Jun 30, 2025 | 96.00% |
| Mar 31, 2025 | 26.00% |
| Dec 31, 2024 | 80.56% |
| Sep 30, 2024 | 90.94% |
| Jun 30, 2024 | 86.18% |
| Mar 31, 2024 | 89.30% |
| Dec 31, 2023 | 87.96% |
| Sep 30, 2023 | 78.23% |
| Jun 30, 2023 | 75.03% |
| Mar 31, 2023 | 74.66% |
| Dec 31, 2022 | 38.18% |
| Sep 30, 2022 | 40.14% |
| Jun 30, 2022 | 62.03% |
| Mar 31, 2022 | 64.22% |
| Dec 31, 2021 | 78.08% |
| Sep 30, 2021 | 52.56% |